Biomed Rep 13(3): 14

Acute myocardial infarction with cardiogenic shock in a young physically active physician concurrently using the anabolic steroid sustanon: A case report

^{Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan}

^{Department of Internal Medicine, Interventional Cardiology Division, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan}

^{Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan}

Correspondence to: Dr Nasr Alrabadi, Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Petra Street, Irbid 22110, Jordan oj.ude.tsuj@idabarlann

Dr Mohamad Ismail Jarrah, Department of Internal Medicine, Interventional Cardiology Division, Faculty of Medicine, Jordan University of Science and Technology, Petra Street, Irbid 22110, Jordan oj.ude.tsuj@harrajim

Received 2019 Oct 31; Accepted 2020 Feb 5.

Abstract

The association between ischemic heart disease (IHD) and the concurrent use of anabolic androgenic steroids (AASs) is underestimated in clinical settings. The tendency of patients to not disclose AASs use may explain this underestimation. In the present case report, the clinical case of a 26-year-old physically active male, who was a physician, without any classical coronary risk factors, who presented with chest pain that was misdiagnosed by the peripheral care unit as skeletal muscle pain is described. Later, the patient was brought to our central hospital (King Abdullah University Hospital) suffering from a massive acute myocardial infarction with marked ECG changes and cardiogenic shock. Following stabilization of his condition, a detailed history of the patient was taken, during which the patient admitted that he was a chronic user of the anabolic steroid sustanon (250 mg, once/week for 6 months) and amino acid supplements (whey protein isolate, 6 tabs every day for 1 year). Specific cardiac markers were increased and the patient exhibited dynamic ischemic changes in his electrocardiogram. Notably, the coronary angiogram of the patient demonstrated ostial occlusion of the left anterior descending artery, which was associated with mid-right coronary artery embolic obstruction. Other than the anabolic steroids and protein supplementation use, the patient history, examination and lab evaluation were normal. During follow up, the patient continued to suffer heart failure with low ejection fraction. In addition, he developed apical thrombus 2 months after primary admission. The patient developed tachycardia in spite of optimal medical treatment and finally received an implantable cardioverter defibrillator. Physicians should always be aware of the possibility of AASs use in young physically active patients. IHD should always be suspected and investigated with typical chest pain in healthy young patients, even if regular risk factors are not present. Medical professionals should not be excluded as potential AASs users/abusers.

Keywords: acute myocardial infarction, cardiogenic shock, anabolic steroids, thrombosis, sustanon

Abstract

Acknowledgements

Not applicable.

Acknowledgements

References

1. Santos RP, Pereira A, Guedes H, Lourenço C, Azevedo J, Pinto PAnabolic drugs and myocardial infarction-a clinical case report. Arq Bras Cardiol. 2015;105:316–319. doi: 10.5935/abc.20150111. (In English, Portuguese) ] [[Google Scholar]
2. Stergiopoulos K, Brennan JJ, Mathews R, Setaro JF, Kort SAnabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature. Vasc Health Risk Manag. 2008;4:1475–1480. doi: 10.2147/vhrm.s4261.] [[Google Scholar]
3. Luijkx T, Velthuis BK, Backx FJ, Buckens CF, Prakken NH, Rienks R, Mali WP, Cramer MJAnabolic androgenic steroid use is associated with ventricular dysfunction on cardiac MRI in strength trained athletes. Int J Cardiol. 2013;167:664–668. doi: 10.1016/j.ijcard.2012.03.072.] [[PubMed][Google Scholar]
4. Kersey RD, Elliot DL, Goldberg L, Kanayama G, Leone JE, Pavlovich M, Pope HG JrNational athletic trainers' association position statement: Anabolic-androgenic steroids. J Athl Train. 2012;47:567–588. doi: 10.4085/1062-6050-47.5.08. National Athletic Trainers' Association. ] [[Google Scholar]
5. Christou GA, Christou KA, Nikas DN, Goudevenos JAAcute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: A case report and critical review of the literature. Eur J Prev Cardiol. 2016;23:1785–1796. doi: 10.1177/2047487316651341.] [[PubMed][Google Scholar]
6. Peoples K, Kobe D, Campana C, Simon EHyperhomocysteinemia-induced myocardial infarction in a young male using anabolic steroids. Am J Emerg Med. 2014;32:948.e1–2. doi: 10.1016/j.ajem.2014.01.041.] [[PubMed][Google Scholar]
7. Ilhan E, Demirci D, Güvenç TS, Calık ANAcute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. Turk Kardiyol Dern Ars. 2010;38:275–278.[PubMed][Google Scholar]
8. Wysoczanski M, Rachko M, Bergmann SRAcute myocardial infarction in a young man using anabolic steroids. Angiology. 2008;59:376–378. doi: 10.1177/0003319707304883.] [[PubMed][Google Scholar]
9. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BHEffects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) Br J Sports Med. 2004;38:253–259. doi: 10.1136/bjsm.2003.000199.] [[Google Scholar]
10. Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, Karch SBSudden cardiac death during anabolic steroid abuse: Morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 2007;121:48–53. doi: 10.1007/s00414-005-0055-9.] [[PubMed][Google Scholar]
11. Kennedy MC, Corrigan AB, Pilbeam STMyocardial infarction and cerebral haemorrhage in a young body builder taking anabolic steroids. Aust N Z J Med. 1993;23(713) doi: 10.1111/j.1445-5994.1993.tb04734.x.] [[PubMed][Google Scholar]
12. Lyngberg KKMyocardial infarction and death of a body builder after using anabolic steroids. Ugeskr Laeger. 1991;153:587–588. (In Danish) [[PubMed][Google Scholar]
13. Pilo R, Aharony D, Raz ATestosterone potentiation of ionophore and ADP induced platelet aggregation: Relationship to arachidonic acid metabolism. Thromb Haemost. 1981;46:538–542.[PubMed][Google Scholar]
14. Kokkonen L, Anttonen O, Penttilä O, Voutilainen SProtein C deficiency and use of anabolic steroids behind the myocardial infarction in a young man. Duodecim. 2001;117:2279–2281. (In Finnish) [[PubMed][Google Scholar]
15. Buttner A, Sachs H, Mall G, Tutsch-Bauer E, Weis SProgressive idiopathic bilateral striato-pallido-dentate calcinosis (Fahr's disease) in a person with anabolic steroid abuse. Leg Med (Tokyo) 2001;3:114–118. doi: 10.1016/s1344-6223(01)00014-1.] [[PubMed][Google Scholar]
16. Sonmez E, Turkdogan KA, Yilmaz C, Kucukbuzcu S, Ozkan A, Sogutt OChronic anabolic androgenic steroid usage associated with acute coronary syndrome in bodybuilder. Turk J Emerg Med. 2016;16:35–37. doi: 10.1016/j.tjem.2014.11.001.] [[Google Scholar]
17. Skogastierna C, Hotzen M, Rane A, Ekström LA supraphysiological dose of testosterone induces nitric oxide production and oxidative stress. Eur J Prev Cardiol. 2014;21:1049–1054. doi: 10.1177/2047487313481755.] [[PubMed][Google Scholar]
18. Tischer KH, Heyny-von Haussen R, Mall G, Doenecke PCoronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids. Z Kardiol. 2003;92:326–331. doi: 10.1007/s00392-003-0915-6. (In German) [] [[PubMed][Google Scholar]
19. Phillis BD, Abeywardena MY, Adams MJ, Kennedy JA, Irvine RJNandrolone potentiates arrhythmogenic effects of cardiac ischemia in the rat. Toxicol Sci. 2007;99:605–611. doi: 10.1093/toxsci/kfm186.] [[PubMed][Google Scholar]
20. Sculthorpe N, Grace F, Jones P, Davies BEvidence of altered cardiac electrophysiology following prolonged androgenic anabolic steroid use. Cardiovasc Toxicol. 2010;10:239–243. doi: 10.1007/s12012-010-9090-y.] [[PubMed][Google Scholar]
21. Maior AS, Carvalho AR, Marques-Neto SR, Menezes P, Soares PP, Nascimento JHCardiac autonomic dysfunction in anabolic steroid users. Scand J Med Sci Sports. 2013;23:548–555. doi: 10.1111/j.1600-0838.2011.01436.x.] [[PubMed][Google Scholar]
22. Kasikcioglu E, Oflaz H, Umman B, Bugra ZAndrogenic anabolic steroids also impair right ventricular function. Int J Cardiol. 2009;134:123–125. doi: 10.1016/j.ijcard.2007.12.027.] [[PubMed][Google Scholar]
23. Frati P, Busardò FP, Cipolloni L, Dominicis ED, Fineschi VAnabolic androgenic steroid (AAS) related deaths: Autoptic, histopathological and toxicological findings. Curr Neuropharmacol. 2015;13:146–159. doi: 10.2174/1570159X13666141210225414.] [[Google Scholar]
24. Gheshlaghi F, Piri-Ardakani MR, Masoumi GR, Behjati M, Paydar PCardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes. J Res Med Sci. 2015;20:165–168.[Google Scholar]